Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for ...

Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT ...

SunHydrogen, Inc. (OTC: HYSR) is pleased to announce the promotion of Dr. Syed Mubeen to the position of Chief Technology Officer (CTO) and the appointment of Hans-Peter Klein as Business Operations ...

Professor Cinzia Casiraghi has been appointed as Chief Scientific Officer (CSO) at the Graphene Engineering Innovation Centre ...

We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific ...

Prior to her new role at Zenas, she served as the Chief Operating Officer at Tabby Therapeutics and held various leadership positions at Jounce Therapeutics, TESARO, Rhythm Pharmaceuticals ...

Dr. Vincent, who previously served as Chief Scientific Officer at Affini-T Therapeutics and held leadership roles at Takeda and Sanofi, remarked on the potential of Korro’s RNA-editing ...